Innate Pharma S.A. (IPHA)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 2.4700 |
| Open | 2.4200 |
| Bid | 2.2100 x 900 |
| Ask | 2.7500 x 1000 |
| Day's range | 2.2800 - 2.4300 |
| 52-week range | 2.0000 - 7.2000 |
| Volume | |
| Avg. volume | 7,982 |
| Market cap | 190.528M |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6940 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.03 |
- Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
MARSEILLE, France, September 23, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that lacutamab, an anti-KIR3DL2 antibody, demonstrated clinical responses in patients with mycosis fungoides (MF), in the ongoing Phase 2 TELLOMAK clinical trial.
- Business Wire
Innate Pharma Reports First Half 2022 Financial Results and Business Update
MARSEILLE, France, September 15, 2022--Innate Pharma reports first half 2022 financial results and business update
- Business Wire
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
MARSEILLE, France, September 08, 2022--Innate Pharma announces conference call and webcast for first half 2022 business update
© 2022 Yahoo. All rights reserved.
